Compositions and methods are provided for treating burns to minimize hyperkalemia, hyponatremia, blistering, and pain by externally applying gel mixture on burn areas from onset of burn shock. The substrate is a gel mixture containing concentrated sodium ion to create a concentration gradient, allowing in situ diffusion of sodium ion (in vitro) into blister, edema, and extracellular fluids (in vivo) to reduce hyponatremia and (in situ), delivering pH control constituents in vivo to prevent initial acidosis, and minimizing subsequent alkalosis and normalizing SID while simultaneously in situ expelling potassium ions in vitro from the same fluids transdermally while restoring the normal homeostasis condition in the human body. The in situ restoration of homeostasis and electrophysiological conditions also brings blister minimization and pain relief while retarding transcapillary vascular fluid loss to defend kidney and cardiac functions by rectifying transmembrane potential across skeletal, neural, cardiac, and renal cell membranes.

Compositions and methods are provided for treating burns to minimize hyperkalemia, hyponatremia, blistering, and pain by externally applying gel mixture on burn areas from onset of burn shock. The substrate is a gel mixture containing concentrated sodium ion to create a concentration gradient, allowing in situ diffusion of sodium ion (in vitro) into blister, edema, and extracellular fluids (in vivo) to reduce hyponatremia and (in situ), delivering pH control constituents in vivo to prevent initial acidosis, and minimizing subsequent alkalosis and normalizing SID while simultaneously in situ expelling potassium ions in vitro from the same fluids transdermally while restoring the normal homeostasis condition in the human body. The in situ restoration of homeostasis and electrophysiological conditions also brings blister minimization and pain relief while retarding transcapillary vascular fluid loss to defend kidney and cardiac functions by rectifying transmembrane potential across skeletal, neural, cardiac, and renal cell membranes.

Provided herein are in vivo gelling ophthalmic pre-formulations forming a biocompatible retinal patch comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the retinal patch at least partially adheres to the site of a retinal tear. Also provided herein are methods of treating retinal detachment by delivering an in vivo gelling ophthalmic pre-formulation to the site of a retinal tear in human eye, wherein the in vivo gelling ophthalmic pre-formulation forms a retinal patch.

Provided herein are in vivo gelling ophthalmic pre-formulations forming a biocompatible retinal patch comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the retinal patch at least partially adheres to the site of a retinal tear. Also provided herein are methods of treating retinal detachment by delivering an in vivo gelling ophthalmic pre-formulation to the site of a retinal tear in human eye, wherein the in vivo gelling ophthalmic pre-formulation forms a retinal patch.

The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.

The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.

The present invention relates to the pharmaceutical composition comprising Zonisamide and one or more pharmaceutically acceptable excipients and also relates to the process for the preparation of the pharmaceutical composition comprising Zonisamide.

The present invention relates to the pharmaceutical composition comprising Zonisamide and one or more pharmaceutically acceptable excipients and also relates to the process for the preparation of the pharmaceutical composition comprising Zonisamide.

The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding a polypeptide; viruses comprising the recombinant nucleic acids; compositions comprising the recombinant nucleic acids and/or viruses; methods of their use; and articles of manufacture or kits thereof.

The disclosure relates to methods and compositions to treat an eosinophilic disease or disorder. More particularly, the disclosure provides methods and compositions for treating eosinophilic esophagitis.